Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Intellia Thera CS (NTLA)

Intellia Thera CS (NTLA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Intellia Thera CS 40 Erie Street Suite 130 Cambridge MA 02139 USA

www.intelliatx.com P: 857-285-6200

Description:

Intellia Therapeutics is a leading clinical-stage genome editing company focused on developing CRISPR/Cas9-based therapeutics. The company is pursuing two primary approaches to fully realize the transformative potential of CRISPR/Cas9 in vivo programs that use intravenously administered CRISPR as the therapy and ex vivo programs that use CRISPR to create the therapy by using engineered human cells.'

Key Statistics

Overview:

Market Capitalization, $K 2,041,614
Enterprise Value, $K 1,814,864
Shares Outstanding, K 96,439
Annual Sales, $ 36,280 K
Annual Net Income, $ -481,190 K
Last Quarter Sales, $ 11,990 K
Last Quarter Net Income, $ -122,220 K
EBIT, $ -485,490 K
EBITDA, $ -476,510 K
60-Month Beta 1.77
% of Insider Shareholders 3.00%
% of Institutional Shareholders 88.77%
Float, K 93,546
% Float 97.00%
Short Volume Ratio 0.54

Growth:

1-Year Return -44.90%
3-Year Return -72.42%
5-Year Return 33.73%
5-Year Revenue Growth 19.22%
5-Year Earnings Growth -173.74%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -1.46 on 02/22/24
Latest Earnings Date 05/02/24
Earnings Per Share ttm -5.35
EPS Growth vs. Prev Qtr -5.80%
EPS Growth vs. Prev Year -4.29%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

NTLA Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -43.91%
Return-on-Assets % -36.42%
Profit Margin % -1,326.32%
Debt/Equity 0.00
Price/Sales 57.24
Price/Cash Flow N/A
Price/Book 1.86
Book Value/Share 11.72
Interest Coverage -3.13
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar